SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Francois Niels)
 

Sökning: WFRF:(Francois Niels) > Real-world treatmen...

  • Abildgaard, NielsHematology Research Unit, Department of Hematology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark (författare)

Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden : An analysis using linked Nordic registries

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • Elsevier,2024
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:umu-221851
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-221851URI
  • https://doi.org/10.1016/j.ejca.2024.113921DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Aim: The Health outcomes and Understanding of MyelomA multi-National Study (HUMANS) was a large-scale, retrospective study conducted across Denmark, Finland and Sweden using linked data from national registries. We describe the characteristics, treatment patterns and clinical outcomes for patients with newly diagnosed multiple myeloma (NDMM) over 2010–2018.Methods: Patients with NDMM who received MM-specific, first-line treatments, were categorised by treatment (autologous stem cell transplantation [ASCT] or a combination chemotherapy regimen based on bortezomib, lenalidomide or melphalan-prednisolone-thalidomide).Results: 11,023 patients received treatment over 2010–2018. Time between diagnosis and treatment was shortest in Denmark (0.9 months), then Sweden (2.9 months) and Finland (4.6 months). Around one third of patients underwent ASCT. Lenalidomide-based regimens were prescribed to 23–28% of patients in Denmark and Finland, versus 12% in Sweden. Patients receiving lenalidomide had the longest wait for treatment, from 3.2 months (Denmark) to 12.1 months (Sweden). Treatment persistence was highest among patients receiving melphalan-prednisolone-thalidomide (7–8 months) in Finland and Sweden and lowest among those receiving bortezomib (3.5 months) in Finland. Overall survival (OS) was longest among patients with ASCT (7–10 years). Among patients receiving chemotherapy, OS (from diagnosis/treatment initiation), varied between cohorts. In a sensitivity analysis excluding patients with smouldering MM, OS decreased for all; for patients receiving bortezomib or lenalidomide, OS from diagnosis was 40–49 and 27–54 months, respectively.Conclusions: This population-based study of patients with NDMM receiving first-line MM-specific treatment, provides real-world data on treatment patterns and outcomes to complement data from randomised clinical trials.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Anttila, PekkaComprehensive Cancer Center, Department of Hematology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland (författare)
  • Waage, AndersDepartment of Hematology, St Olav's University Hospital, Trondheim, Norway (författare)
  • Rubin, Katrine HassResearch Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense, Denmark (författare)
  • Ørstavik, SigurdTakeda Pharmaceuticals International AG, Oslo, Norway (författare)
  • Bent-Ennakhil, NawalTakeda Pharmaceuticals International AG, Zurich, Switzerland (författare)
  • Gavini, FrançoisTakeda Pharmaceuticals International AG, Zurich, Switzerland (författare)
  • Ma, YuanjunParexel International, Stockholm, Sweden (författare)
  • Freilich, JonatanUmeå universitet,Dermatologi och venereologi,Parexel International, Stockholm, Sweden(Swepub:umu)jofr0238 (författare)
  • Hansson, MarkusSahlgrenska Academy and Sahlgrenska University Hospital, Göteborg, Sweden (författare)
  • Hematology Research Unit, Department of Hematology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, DenmarkComprehensive Cancer Center, Department of Hematology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:European Journal of Cancer: Elsevier2010959-80491879-0852

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy